Detalhe da pesquisa
1.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med
; 387(8): 704-714, 2022 08 25.
Artigo
Inglês
| MEDLINE | ID: mdl-36001711
2.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33259589
3.
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Blood
; 134(21): 1811-1820, 2019 11 21.
Artigo
Inglês
| MEDLINE | ID: mdl-31558467
4.
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Lancet Oncol
; 19(4): 486-496, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29475723
5.
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
Br J Haematol
; 177(2): 243-253, 2017 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28220479
6.
Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial.
Br J Haematol
; 176(3): 412-420, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-27982425
7.
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Blood Adv
; 8(2): 378-387, 2024 01 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37871300
8.
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy.
Front Immunol
; 14: 1130052, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37153563
9.
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Clin Cancer Res
; 28(18): 3958-3964, 2022 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35852793
10.
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Lancet Haematol
; 8(4): e254-e266, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33631112
11.
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
J Clin Oncol
; 39(15): 1609-1618, 2021 05 20.
Artigo
Inglês
| MEDLINE | ID: mdl-33683917
12.
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Blood Adv
; 5(23): 5332-5343, 2021 12 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34547767
13.
The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
Blood Adv
; 4(13): 3072-3084, 2020 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-32634240
14.
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Lancet Haematol
; 6(2): e100-e109, 2019 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-30709431
15.
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Lancet Haematol
; 6(1): e38-e47, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-30558987
16.
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Leuk Lymphoma
; 64(9): 1579-1582, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37341984